# Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

> **NCT00733408** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 59 (actual)

## Conditions studied

- Estrogen Receptor-negative Breast Cancer
- HER2-negative Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer
- Triple-negative Breast Cancer

## Interventions

- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation
- **BIOLOGICAL:** bevacizumab
- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00733408
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-23
- **Primary completion:** 2017-07-05
- **Final completion:** 2017-09-28
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00733408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00733408, "Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00733408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*